We report in vivo selection of a severe acute respiratory syndrome coronavirus 2 spike mutation (Q493R) conferring simultaneous resistance to bamlanivimab and etesivimab. This mutation was isolated from a patient who had coronavirus disease and was treated with these drugs.
All Keywords
【저자키워드】 COVID-19, Treatment, coronavirus disease, severe acute respiratory syndrome coronavirus 2, viruses, respiratory infections, zoonoses, SARS-CoV-2, Coronaviruses, variant, Italy, Spike protein, spike protein escape mutation Q493R, receptor-binding motif, bamlaniv/etesevimab, 【초록키워드】 coronavirus disease, coronavirus, Mutation, drugs, bamlanivimab, spike mutation, Patient, respiratory, in vivo, acute respiratory syndrome, treated, 【제목키워드】 spike, Spike protein, emergence, escape,
【저자키워드】 COVID-19, Treatment, coronavirus disease, severe acute respiratory syndrome coronavirus 2, viruses, respiratory infections, zoonoses, SARS-CoV-2, Coronaviruses, variant, Italy, Spike protein, spike protein escape mutation Q493R, receptor-binding motif, bamlaniv/etesevimab, 【초록키워드】 coronavirus disease, coronavirus, Mutation, drugs, bamlanivimab, spike mutation, Patient, respiratory, in vivo, acute respiratory syndrome, treated, 【제목키워드】 spike, Spike protein, emergence, escape,
우리는 밤라니비맙과 에테시비맙에 동시 내성을 부여하는 중증 급성 호흡기 증후군 코로나바이러스 2 스파이크 돌연변이(Q493R)의 생체 내 선택을 보고합니다. 이 돌연변이는 코로나바이러스 질환에 걸린 환자로부터 분리되었으며 이러한 약물로 치료되었습니다.